Sort
51,593 grants matching “hepatitis”
Understanding human antibody responses to chronic viral hepatitis C
$621,806Mansun Law · Scripps Research Institute, The · R01 · FY2023 · AI
Impact of harm reduction care in HIV clinical settings on stigma and health outcomes for PLWH who use drugs
$621,799Mary Elizabeth Hawk · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · DA
Human Vaccine Durability using Integrated Bioinformatics and a Novel in vitro Bone Marrow Mimic
$621,751Frances Eun-Hyung Lee · Emory University · U01 · FY2022 · AI
Molecular analysis of mother-to-child transmission of hepatitis B virus
$621,698J.-H. James Ou · University Of Southern California · R01 · FY2025 · AI
Lymphatics in the liver
$621,696Yasuko Iwakiri · Yale University · R01 · FY2022 · DK
Iron Status: A Pathway Analysis in Multiple Ethnicities
$621,640Christine E McLaren · University Of California-Irvine · R01 · FY2007 · HL
University of Washington Vaccine and Treatment Evaluation Unit
$621,600Anna Wald · University Of Washington · UM1 · FY2022 · AI
STD and AIDS Research Training Grant
$621,508Sheila A. Lukehart · University Of Washington · T32 · FY2014 · AI
Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant
$621,488Peter G Stock · University Of California, San Francisco · U01 · FY2017 · AI
We are here now - a multi-level, multi-component sexual and reproductive health intervention for American Indian youth
$621,479Elizabeth Lynne Rink · Montana State University - Bozeman · R01 · FY2020 · MD
Body Composition & REE Responses to Bariatric Surgeries
$621,477Dympna Gallagher · St. Luke'S-Roosevelt Inst For Hlth Scis · R01 · FY2014 · DK
Regulation of Hepatic Lipid and Glucose Metabolism by PC-TP/StarD2
$621,301David E Cohen · Weill Medical Coll Of Cornell Univ · R37 · FY2017 · DK
Community-based, client-centered prevention homes to address the rural opioid epidemic
$621,231Ryan Patrick Westergaard · University Of Wisconsin-Madison · UG3 · FY2017 · DA
CSDE1 as a Post Transcriptional Regulator of the LDLR
$621,179John S Chorba · University Of California, San Francisco · R01 · FY2024 · HL
HIV HCV Coinfection Antiviral Therapy and Fibrosis
$621,175David L Thomas · Johns Hopkins University · R37 · FY2014 · DA
Cyanobacteria, cyanotoxins, and liver cancer development
$621,174Brenda Y Hernandez · University Of Hawaii At Manoa · U01 · FY2024 · CA
Inhibitors and Probes of HIV-1 Cell Fusion
$621,127Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Inhibitors and Probes of HIV-1 Cell Fusion
$621,127Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
HIV Neutralization Inhibitors: Engineering, characterization, and functions
$621,127Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Probing the antibody response to HCV to facilitate rational immunogen design
$621,118Dennis R. Burton · Scripps Research Institute, The · R01 · FY2012 · AI
PCB-mediated dysbiosis of the gut microbiome: A missing link in PCB-mediated neurodevelopmental disorders?
$621,086Hans-Joachim Lehmler · University Of Iowa · R01 · FY2021 · ES
Gigapixel digital PCR in Giant Unilamellar Vesicles
$621,029Adam R. Abate · University Of California, San Francisco · R01 · FY2021 · EB
Behavioral Assessment and Medical (BAM) Core
$620,958Robert Kernachan Heaton · University Of California, San Diego · P50 · FY2014 · DA
Models of AT Deficiency Using Human Hepatocytes
$620,929Ira J. Fox · Washington University · P01 · FY2020 · DK
The altered lipid and protein metabolism of pediatric patients with HIV infection
$620,915Farook Jahoor · Baylor College Of Medicine · R01 · FY2008 · HD